Latest & greatest articles for dementia

The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical guidelines, regulatory guidance, clinical trials and many other forms of evidence. If you wanted the latest trusted evidence on dementia or other clinical topics then use Trip today.

This page lists the very latest high quality evidence on dementia and also the most popular articles. Popularity measured by the number of times the articles have been clicked on by fellow users in the last twelve months.

What is Trip?

Trip is a clinical search engine designed to allow users to quickly and easily find and use high-quality research evidence to support their practice and/or care.

Trip has been online since 1997 and in that time has developed into the internet’s premier source of evidence-based content. Our motto is ‘Find evidence fast’ and this is something we aim to deliver for every single search.

As well as research evidence we also allow clinicians to search across other content types including images, videos, patient information leaflets, educational courses and news.

For further information on Trip click on any of the questions/sections on the left-hand side of this page. But if you still have questions please contact us via jon.brassey@tripdatabase.com

Top results for dementia

181. Omega-3 fatty acids for the treatment of dementia. (Abstract)

Omega-3 fatty acids for the treatment of dementia. Omega-3 polyunsaturated fatty acids (omega-3 PUFAs) from fish and plant sources are commonly considered as a promising non-medical alternative to improve brain functions and slow down the progression of dementia. This assumption is mostly based on findings of preclinical studies and epidemiological research. Resulting explanatory models aim at the role omega-3 PUFAs play in the development and integrity of the brain's neurons, their protective (...) antioxidative effect on cell membranes and potential neurochemical mechanisms directly related to Alzheimer-specific pathology. Epidemiological research also found evidence of malnutrition in people with dementia. Considering this and the fact that omega-3 PUFA cannot be synthesised by humans, omega-3 PUFAs might be a promising treatment option for dementia.To assess the efficacy and safety of omega-3 polyunsaturated fatty acid (PUFA) supplementation for the treatment of people with dementia.We searched

2016 Cochrane

182. Validation of the Spanish version of the Edinburgh feeding evaluation in dementia scale applied to institutionalized older persons with dementia: a study protocol Full Text available with Trip Pro

Validation of the Spanish version of the Edinburgh feeding evaluation in dementia scale applied to institutionalized older persons with dementia: a study protocol The aim of this study was to obtain a Spanish version of the Edinburgh Feeding Evaluation in Dementia Scale version, to assess its reliability for use by medical staff and caregivers at residential care homes, to evaluate by confirmatory methods its construct validity. A further aim was to determine the criterion validity with respect (...) to biochemical markers of malnutrition such as serum albumin, transferrin, cholesterol and lymphocytes, the body mass index and the mini nutritional assessment.Clinimetric cross-validation study.Institutionalized subjects with dementia will be observed while consuming meals and evaluated with the instrument independently by nurses and caregivers.

2016 Nursing open

183. Comorbidity and dementia: a mixed-method study on improving health care for people with dementia (CoDem)

Comorbidity and dementia: a mixed-method study on improving health care for people with dementia (CoDem) Comorbidity and dementia: a mixed-method study on improving health care for people with dementia (CoDem) Comorbidity and dementia: a mixed-method study on improving health care for people with dementia (CoDem) Bunn F, Burn A-M, Goodman C, Robinson L, Rait G, Norton S, Bennett H, Poole M, Schoeman J, Brayne C Record Status This is a bibliographic record of a published health technology (...) assessment from a member of INAHTA. No evaluation of the quality of this assessment has been made for the HTA database. Citation Bunn F, Burn A-M, Goodman C, Robinson L, Rait G, Norton S, Bennett H, Poole M, Schoeman J, Brayne C. Comorbidity and dementia: a mixed-method study on improving health care for people with dementia (CoDem) Health Services and Delivery Research 2016; 4(8) Authors' objectives To explore the impact of dementia on access to non-dementia services and identify ways of improving

2016 Health Technology Assessment (HTA) Database.

184. Diagnosis and Disruption: Population-Level Analysis Identifying Points of Care at Which Transitions Are Highest for People with Dementia and Factors That Contribute to Them Full Text available with Trip Pro

Diagnosis and Disruption: Population-Level Analysis Identifying Points of Care at Which Transitions Are Highest for People with Dementia and Factors That Contribute to Them To examine transitions that individuals with dementia experience longitudinally and to identify points of care when transitions are highest and the factors that contribute to those transitions.Population-based 10-year retrospective cohort study from 2000 to 2011.General community.All individuals aged 65 and older newly (...) diagnosed with dementia in British Columbia, Canada.The frequency and timing of transitions over 10 years, participant characteristics associated with greater number of transitions, and the influence of recommended dementia care and high-quality primary care on number of transitions.Individuals experience a spike in transitions during the year of diagnosis, driven primarily by hospitalizations, despite accounting for end of life or newly moving to a long-term care facility (LTCF). This occurs regardless

2016 EvidenceUpdates

185. The frontotemporal dementia-motor neuron disease continuum. (Abstract)

The frontotemporal dementia-motor neuron disease continuum. Early reports of cognitive and behavioural deficits in motor neuron disease might have been overlooked initially, but the concept of a frontotemporal dementia-motor neuron disease continuum has emerged during the past decade. Frontotemporal dementia-motor neuron disease is now recognised as an important dementia syndrome, which presents substantial challenges for diagnosis and management. Frontotemporal dementia, motor neuron disease (...) , and frontotemporal dementia-motor neuron disease are characterised by overlapping patterns of TAR DNA binding protein (TDP-43) pathology, while the chromosome 9 open reading frame 72 (C9orf72) repeat expansion is common across the disease spectrum. Indeed, the C9orf72 repeat expansion provides important clues to disease pathogenesis and suggests potential therapeutic targets. Variable diagnostic criteria identify motor, cognitive, and behavioural deficits, but further refinement is needed to define the clinical

2016 Lancet

186. Clinical practice guidelines and principles of care for people with dementia

Clinical practice guidelines and principles of care for people with dementia CLINICAL PRACTICE GUIDELINES AND PRINCIPLES OF CARE FOR PEOPLE WITH DEMENTIA 2016 ii © NHMRC Partnership Centre for Dealing with Cognitive and Related Functional Decline in Older People 2016 ISBN Print: 978-0-9945415-1-2 ISBN Online: 978-0-9945415-0-5 Published: February 2016 Suggested citation: Guideline Adaptation Committee. Clinical Practice Guidelines and Principles of Care for People with Dementia. Sydney (...) People. The Partnership Centre receives support from the NHMRC and Funding Partners including HammondCare, Alzheimer’s Australia, Brightwater Care Group and Helping Hand Aged Care. Members of the Guideline Adaptation Committee generously contributed their time to assist in the development of this Guideline. Consumers have played a key role in the development of this Guideline and their input has been critical to ensuring the document remains relevant to the needs of people with dementia

2016 Clinical Practice Guidelines Portal

187. Comorbidity and dementia: a mixed-method study on improving health care for people with dementia (CoDem) Full Text available with Trip Pro

Comorbidity and dementia: a mixed-method study on improving health care for people with dementia (CoDem) Comorbidity and dementia: a mixed-method study on improving health care for people with dementia (CoDem) Journals Library An error occurred retrieving content to display, please try again. >> >> >> Page Not Found Page not found (404) Sorry - the page you requested could not be found. Please choose a page from the navigation or try a website search above to find the information you need

2016 NIHR HTA programme

188. Validation of the Parkinson's Disease‐Cognitive Rating Scale Applying the Movement Disorder Society Task Force Criteria for Dementia Associated with Parkinson's Disease Full Text available with Trip Pro

Validation of the Parkinson's Disease‐Cognitive Rating Scale Applying the Movement Disorder Society Task Force Criteria for Dementia Associated with Parkinson's Disease The authors studied the measurement properties of the Parkinson's Disease-Cognitive Rating Scale (PD-CRS) compared with Movement Disorders Society Task Force (MDS-TF) criteria for the diagnosis of dementia in patients with Parkinson's disease.The sample consisted of 223 patients who were diagnosed in accordance with the United (...) was analyzed.The internal consistency was shown to be adequate, with a λ value of 0.821. A floor effect was observed in 4 of the items (Sustained Attention, Working Memory, Immediate Verbal Memory, and Alternating Verbal Fluency), and 1 item showed a ceiling effect (Clock Copying). The scale adequately discriminated patients with and without dementia (Kruskal-Wallis; P ≤ 0.000). The area under the curve was 0.899. With a cutoff score of 62 (from a possible score of 134), the scale achieved 94% sensitivity

2016 Movement disorders clinical practice

189. Is Dementia in Decline? Historical Trends and Future Trajectories. (Abstract)

Is Dementia in Decline? Historical Trends and Future Trajectories. 26863352 2016 02 24 2016 02 11 1533-4406 374 6 2016 Feb 11 The New England journal of medicine N. Engl. J. Med. Is Dementia in Decline? Historical Trends and Future Trajectories. 507-9 10.1056/NEJMp1514434 Jones David S DS From the Department of Global Health and Social Medicine, Harvard Medical School, Boston (D.S.J); the Department of the History of Science, Harvard University, Cambridge, MA (D.S.J.); and the Division (...) of General Internal Medicine and the Department of the History of Medicine, Johns Hopkins University School of Medicine, Baltimore (J.A.G.). Greene Jeremy A JA eng Historical Article Journal Article United States N Engl J Med 0255562 0028-4793 AIM IM Coronary Artery Disease epidemiology history Dementia epidemiology history History, 20th Century History, 21st Century Humans Prevalence United States epidemiology 2016 2 11 6 0 2016 2 11 6 0 2016 2 26 6 0 ppublish 26863352 10.1056/NEJMp1514434

2016 NEJM

190. Incidence of Dementia over Three Decades in the Framingham Heart Study. Full Text available with Trip Pro

Incidence of Dementia over Three Decades in the Framingham Heart Study. The prevalence of dementia is expected to soar as the average life expectancy increases, but recent estimates suggest that the age-specific incidence of dementia is declining in high-income countries. Temporal trends are best derived through continuous monitoring of a population over a long period with the use of consistent diagnostic criteria. We describe temporal trends in the incidence of dementia over three decades (...) among participants in the Framingham Heart Study.Participants in the Framingham Heart Study have been under surveillance for incident dementia since 1975. In this analysis, which included 5205 persons 60 years of age or older, we used Cox proportional-hazards models adjusted for age and sex to determine the 5-year incidence of dementia during each of four epochs. We also explored the interactions between epoch and age, sex, apolipoprotein E ε4 status, and educational level, and we examined

2016 NEJM

191. Benzodiazepine use and risk of incident dementia or cognitive decline: prospective population based study. Full Text available with Trip Pro

Benzodiazepine use and risk of incident dementia or cognitive decline: prospective population based study. To determine whether higher cumulative use of benzodiazepines is associated with a higher risk of dementia or more rapid cognitive decline.Prospective population based cohort.Integrated healthcare delivery system, Seattle, Washington.3434 participants aged ≥ 65 without dementia at study entry. There were two rounds of recruitment (1994-96 and 2000-03) followed by continuous enrollment (...) beginning in 2004.The cognitive abilities screening instrument (CASI) was administered every two years to screen for dementia and was used to examine cognitive trajectory. Incident dementia and Alzheimer's disease were determined with standard diagnostic criteria. Benzodiazepine exposure was defined from computerized pharmacy data and consisted of the total standardized daily doses (TSDDs) dispensed over a 10 year period (a rolling window that moved forward in time during follow-up). The most recent

2016 BMJ

192. Effects of a Stepwise Multidisciplinary Intervention for Challenging Behavior in Advanced Dementia: A Cluster Randomized Controlled Trial Full Text available with Trip Pro

Effects of a Stepwise Multidisciplinary Intervention for Challenging Behavior in Advanced Dementia: A Cluster Randomized Controlled Trial To assess whether implementation of a stepwise multicomponent intervention (STA OP!) is effective in reducing challenging behavior and depression in nursing home residents with advanced dementia.Cluster randomized controlled trial.Twenty-one clusters (single independent nursing home units) in 12 nursing homes within the Netherlands.Residents with advanced (...) dementia (N = 288).Staff working on intervention units received comprehensive stepwise multidisciplinary training; the control condition received training on general nursing skills, dementia management and pain without the stepwise component.The primary outcome was agitation (Cohen-Mansfield Agitation Inventory (CMAI)). Secondary outcomes included psychotropic medication use, neuropsychiatric symptoms (Neuropsychiatric Inventory-Nursing Home version (NPI-NH)), and symptoms of depression (Cornell Scale

2016 EvidenceUpdates Controlled trial quality: predicted high

193. Effects of a High-Intensity Functional Exercise Program on Dependence in Activities of Daily Living and Balance in Older Adults with Dementia Full Text available with Trip Pro

Effects of a High-Intensity Functional Exercise Program on Dependence in Activities of Daily Living and Balance in Older Adults with Dementia To investigate the effects of a high-intensity functional exercise program on independence in activities of daily living (ADLs) and balance in older people with dementia and whether exercise effects differed between dementia types.Cluster-randomized controlled trial: Umeå Dementia and Exercise (UMDEX) study.Residential care facilities, Umeå (...) , Sweden.Individuals aged 65 and older with a dementia diagnosis, a Mini-Mental State Examination score of 10 or greater, and dependence in ADLs (N=186).Ninety-three participants each were allocated to the high-intensity functional exercise program, comprising lower limb strength and balance exercises, and 93 to a seated control activity.Blinded assessors measured ADL independence using the Functional Independence Measure (FIM) and Barthel Index (BI) and balance using the Berg Balance Scale (BBS) at baseline and 4

2016 EvidenceUpdates Controlled trial quality: predicted high

194. Test Accuracy of Informant-Based Cognitive Screening Tests for Diagnosis of Dementia and Multidomain Cognitive Impairment in Stroke Full Text available with Trip Pro

Test Accuracy of Informant-Based Cognitive Screening Tests for Diagnosis of Dementia and Multidomain Cognitive Impairment in Stroke Poststroke cognitive assessment can be performed using standardized questionnaires designed for family or care givers. We sought to describe the test accuracy of such informant-based assessments for diagnosis of dementia/multidomain cognitive impairment in stroke.We performed a systematic review using a sensitive search strategy across multidisciplinary electronic (...) databases. We created summary test accuracy metrics and described reporting and quality using STARDdem and Quality Assessment of Diagnostic Accuracy Studies (QUADAS) tools, respectively.From 1432 titles, we included 11 studies. Ten papers used the Informant Questionnaire on Cognitive Decline in the Elderly (IQCODE). Four studies described IQCODE for diagnosis of poststroke dementia (n=1197); summary sensitivity: 0.81 (95% confidence interval, 0.60-0.93); summary specificty: 0.83 (95% confidence interval

2016 EvidenceUpdates

195. Different PD-MCI criteria and risk of dementia in Parkinson’s disease: 4-year longitudinal study Full Text available with Trip Pro

Different PD-MCI criteria and risk of dementia in Parkinson’s disease: 4-year longitudinal study The Movement Disorder Society Task Force (MDS-TF) has proposed diagnostic criteria for mild cognitive impairment in Parkinson's disease (PD-MCI). We hypothesized that the risk of dementia (PDD) varies across the different cutoff schemes allowed. A longitudinal study followed 121 non-demented PD patients for up to 4.5 years. In Part One, unique groups of patients were identified as PD-MCI

2016 NPJ Parkinson's disease

196. Amyloid‐Beta Positron Emission Tomography Imaging of Alzheimer's Pathology in Parkinson's Disease Dementia Full Text available with Trip Pro

Amyloid‐Beta Positron Emission Tomography Imaging of Alzheimer's Pathology in Parkinson's Disease Dementia Neuronal loss and α-synuclein (α-syn) pathology are diagnostic of PD in the appropriate clinical context. However, some PD patients have co-morbid Alzheimer's disease (AD) pathology on autopsy, including amyloid-β (Aβ) plaques and neurofibrillary tangles. Florbetapir(18F) is a PET ligand that detects Aβ pathology. We hypothesized that florbetapir(18F) imaging could detect Aβ pathology (...) in Parkinson disease dementia (PDD) patients prior to death.To determine the utility of florbetapir(18F) PET imaging in detecting Aβ pathology in patients with autopsy-confirmed PDD.Five participants with PDD had florbetapir(18F) PET imaging prior to death as a part of a longitudinal research study of cognitive decline in PD. PET scans were evaluated by expert raters blinded to clinical and neuropathological information. At autopsy, all five participants underwent semi-quantitative assessments of regional

2016 Movement disorders clinical practice

197. Miscellaneous: Promoting multilevel primary prevention of depression and diabetes during midlife may protect against dementia

Miscellaneous: Promoting multilevel primary prevention of depression and diabetes during midlife may protect against dementia Promoting multilevel primary prevention of depression and diabetes during midlife may protect against dementia | Evidence-Based Mental Health We use cookies to improve our service and to tailor our content and advertising to you. You can manage your cookie settings via your browser at any time. To learn more about how we use cookies, please see our . Log in using your (...) username and password For personal accounts OR managers of institutional accounts Username * Password * your user name or password? Search for this keyword Search for this keyword Main menu Log in using your username and password For personal accounts OR managers of institutional accounts Username * Password * your user name or password? You are here Promoting multilevel primary prevention of depression and diabetes during midlife may protect against dementia Article Text Electronic pages Miscellaneous

2016 Evidence-Based Mental Health

198. Causes and risk factors: Mediterranean diet and treating diabetes and depression in old age may reduce dementia risk

Causes and risk factors: Mediterranean diet and treating diabetes and depression in old age may reduce dementia risk Mediterranean diet and treating diabetes and depression in old age may reduce dementia risk | Evidence-Based Mental Health We use cookies to improve our service and to tailor our content and advertising to you. You can manage your cookie settings via your browser at any time. To learn more about how we use cookies, please see our . Log in using your username and password (...) For personal accounts OR managers of institutional accounts Username * Password * your user name or password? Search for this keyword Search for this keyword Main menu Log in using your username and password For personal accounts OR managers of institutional accounts Username * Password * your user name or password? You are here Mediterranean diet and treating diabetes and depression in old age may reduce dementia risk Article Text Electronic pages Causes and risk factors Mediterranean diet and treating

2016 Evidence-Based Mental Health

199. Dementia: Report by the Secretariat

Dementia: Report by the Secretariat Dementia: report by the Secretariat JavaScript is disabled for your browser. Some features of this site may not work without it. Toggle navigation Toggle navigation Search Browse Statistics Related Links Dementia: report by the Secretariat View/ Open View Statistics Altmetrics Share Citation Executive Board, 139 . (‎2016)‎. Dementia: report by the Secretariat. World Health Organization. Gov't Doc # EB139/3 Collections Language English Metadata Related items

2016 WHO

200. Clinical practice guidelines for dementia in Australia Full Text available with Trip Pro

Clinical practice guidelines for dementia in Australia Clinical practice guidelines for dementia in Australia | The Medical Journal of Australia mja-search search Use the for more specific terms. Title contains Body contains Date range from Date range to Article type Author's surname Volume First page doi: 10.5694/mja__.______ Search Reset  close Individual Login Purchase options Connect person_outline Login keyboard_arrow_down Individual Login Purchase options menu search Advertisement close (...) Clinical practice guidelines for dementia in Australia Kate Laver, Robert G Cumming, Suzanne M Dyer, Meera R Agar, Kaarin J Anstey, Elizabeth Beattie, Henry Brodaty, Tony Broe, Lindy Clemson, Maria Crotty, Margaret Dietz, Brian M Draper, Leon Flicker, Margeret Friel, Louise Mary Heuzenroeder, Susan Koch, Susan Kurrle, Rhonda Nay, C Dimity Pond, Jane Thompson, Yvonne Santalucia, Craig Whitehead and Mark W Yates Med J Aust 2016; 204 (5): 191-193. || doi: 10.5694/mja15.01339 Published online: 21 March

2016 MJA Clinical Guidelines